Table 3.

Univariate and multivariate analysis of factors associated with progression‐free survival.

Characteristic	HR. (95% CI)	Univariate analysis p-value	HR. (95% CI)	Multivariate analysis p-value
Age group (<40 vs. ≥40)	0.433 (0.224-0.839)	0.013	0.528 (0.238-1.174)	0.117
ECOG performance status (0-1 vs ≥2)	0.419 (0.162-1.088)	0.074	0.440 (0.150-1.295)	0.136
Menstrual status (pre vs. post)	0.454 (0.230-0.896)	0.023	1.156 (0.468-2.860)	0.753
Hormone receptor status (negative vs. positive)	1.982 (1.064-3.692)	0.031	1.426 (0.704-2.885)	0.324
DFI (≤12 months vs.>12 months vs. de novo IV stage)	1.375 (0.564-3.353)	0.484	N/A*	N/A
Number of sites in primary recurrence (1 vs. >1)	1.350 (0.729-2.498)	0.340	N/A	N/A
Number of metastatic sites before inetetamab (1 vs. ≥2)	0.838 (0.447-1.573)	0.583	N/A	N/A
Brain metastasis (no vs. yes)	1.516 (0.731-3.145)	0.263	N/A	N/A
Visceral metastasis (no vs. yes)	1.735 (0.928-3.244)	0.084	2.444 (1.095-5.457)	0.029
Regimens (other therapeutic agents vs. inetetamab + vinorelbine + pyrotinib)	2.167 (1.140-4.119)	0.018	3.543 (1.680-7.471)	0.001

*N/A, Not applicable.